Sedative Drugs in Trauma Unit
Primary Recommendation
For adult trauma patients requiring sedation in the trauma unit, use ketamine (1-2 mg/kg IV) or etomidate (0.2-0.3 mg/kg IV) as first-line rapid-acting sedative agents, with ketamine preferred in hemodynamically unstable patients due to its sympathomimetic properties, though both agents demonstrate equivalent mortality and clinical outcomes. 1, 2
Rapid Sequence Intubation (RSI) Sedation
First-Line Agents
Ketamine vs. Etomidate:
- Both agents show no significant difference in mortality when used for RSI in trauma patients 1, 2
- A large retrospective study (n=968) spanning an institutional protocol change found hospital mortality of 20.4% with ketamine vs. 17.3% with etomidate (adjusted OR 1.41; 95% CI 0.92-2.16, not statistically significant) 2
- No differences in ICU-free days or ventilator-free days between the two agents 2
Dosing Protocols
Ketamine:
- Standard dose: 1-2 mg/kg IV for RSI 1, 2
- Onset: Rapid (30-60 seconds)
- Preserves respiratory drive and airway reflexes 1, 3
- Sympathomimetic properties maintain cardiovascular tone 1, 3
Etomidate:
- Standard dose: 0.2-0.3 mg/kg IV 1
- Reduced dose: 0.15 mg/kg in hemodynamically compromised patients 1
- Most favorable hemodynamic profile among induction agents 1
- Single-dose use does not increase mortality despite adrenal enzyme inhibition 1
Hemodynamic Considerations
For hemodynamically unstable patients:
- Ketamine is preferred due to sympathomimetic effects that support blood pressure and perfusion 1, 3
- Critical caveat: In patients with depleted catecholamine stores (prolonged shock, severe sepsis), ketamine may paradoxically cause hypotension or cardiac arrest 1
- Etomidate remains safe with dose reduction to 0.15 mg/kg 1
- Avoid propofol - causes most profound hypotension of all induction agents 1
- Avoid midazolam - potent venodilator at RSI doses with longer onset 1
Continuous Sedation Protocols
Agent Selection Hierarchy
For mechanically ventilated trauma patients requiring prolonged sedation:
Propofol or Dexmedetomidine over benzodiazepines (conditional recommendation, low quality evidence) 4
- Both reduce time to light sedation and extubation compared to benzodiazepines
- No significant differences between propofol and dexmedetomidine in outcomes 4
Propofol dosing:
Midazolam dosing:
Lorazepam dosing:
Practical Algorithm for Continuous Sedation
Choose based on clinical priorities:
- If rapid wake-up assessment needed (e.g., traumatic brain injury): Use propofol 6
- If hemodynamic stability uncertain: Use midazolam (most titratable, avoids excessive hypotension) 5
- If cost is primary concern: Use lorazepam, but monitor closely for oversedation 5
- If delirium prevention is priority: Consider dexmedetomidine 4, 7
Special Populations
Traumatic Brain Injury
- Propofol and midazolam are equally safe - no differences in ICP, cerebral perfusion pressure, or jugular venous oxygen saturation 6
- Propofol allows faster neurologic assessment due to shorter wake-up time 6
- Ketamine is not contraindicated but requires careful ICP monitoring 8
Severe Hypotension/Shock
- First choice: Etomidate 0.15 mg/kg (most hemodynamically stable) 1
- Second choice: Ketamine 1-2 mg/kg (if catecholamine stores intact) 1, 3
- Avoid: Propofol, midazolam at RSI doses 1
Common Pitfalls
- Using propofol in hemodynamically unstable patients - causes profound hypotension 1
- Assuming ketamine is always safe in shock - depleted catecholamines can lead to cardiovascular collapse 1
- Relying on propofol alone in trauma patients - undersedation occurs frequently (31% of time) 5
- Choosing lorazepam without close monitoring - oversedation is problematic 5
- Avoiding etomidate due to adrenal concerns - single-dose use is safe and does not increase mortality 1
Adjunctive Considerations
- Always combine with opioid analgesia (morphine, fentanyl) for pain control 5, 6
- Use validated sedation scales (Modified Ramsay Scale, RASS) for titration 5
- Target light sedation (cooperative, responsive) when clinically appropriate 7
- Consider benzodiazepine co-administration with ketamine to reduce emergence phenomena 3